NICE Guidance: Durvalumab for Muscle-Invasive Bladder Cancer

NICE Technology Appraisals

Published March 2nd, 2026

Detected March 12th, 2026

Summary

NICE has published technology appraisal guidance (TA1138) recommending durvalumab with gemcitabine and cisplatin for the neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer. The guidance includes information on commercial arrangements and reporting adverse events.

View original document View source feed page

What changed

NICE has issued final guidance (TA1138) recommending the use of durvalumab in combination with gemcitabine and cisplatin for the neoadjuvant treatment of muscle-invasive bladder cancer, followed by durvalumab alone for adjuvant treatment. The guidance, published on March 2, 2026, outlines evidence-based recommendations and notes the existence of a commercial access agreement for durvalumab.

Healthcare professionals are expected to consider this guidance alongside patient needs. Commissioners and providers are responsible for ensuring funding is available and for assessing and reducing the environmental impact of implementation. Adverse events related to the treatment should be reported to the MHRA via the Yellow Card Scheme.

What to do next

Review NICE guidance TA1138 regarding durvalumab for muscle-invasive bladder cancer.
Ensure appropriate funding is available for patients wishing to use this treatment.
Report any adverse events related to durvalumab treatment via the Yellow Card Scheme.

Source document (simplified)

Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer

Technology appraisal guidance
TA1138
Published:

02 March 2026

Download guidance (PDF)

Overview

Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for neoadjuvant treatment and then alone for adjuvant treatment of muscle-invasive bladder cancer in adults.

Last reviewed: 2 March 2026

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Commercial arrangement

There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact Market.AccessUK@astrazeneca.com for details.

Guidance development process

How we develop NICE technology appraisal guidance

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.